Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

BACKGROUND: Ovarian and triple-negative breast cancers with BRCA1 or BRCA2 loss are highly sensitive to treatment with PARP inhibitors and platinum-based cytotoxic agents and show an accumulation of genomic scars in the form of gross DNA copy number aberrations. Cancers without BRCA1 or BRCA2 loss b...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biomark Res
Main Authors: Marquard, Andrea M, Eklund, Aron C, Joshi, Tejal, Krzystanek, Marcin, Favero, Francesco, Wang, Zhigang C, Richardson, Andrea L, Silver, Daniel P, Szallasi, Zoltan, Birkbak, Nicolai J
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2015
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4443545/
https://ncbi.nlm.nih.gov/pubmed/26015868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-015-0033-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki